JP2024541771A5 - - Google Patents
Info
- Publication number
- JP2024541771A5 JP2024541771A5 JP2024531113A JP2024531113A JP2024541771A5 JP 2024541771 A5 JP2024541771 A5 JP 2024541771A5 JP 2024531113 A JP2024531113 A JP 2024531113A JP 2024531113 A JP2024531113 A JP 2024531113A JP 2024541771 A5 JP2024541771 A5 JP 2024541771A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- modified oligonucleotide
- compound
- modified
- items
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163283177P | 2021-11-24 | 2021-11-24 | |
| US63/283,177 | 2021-11-24 | ||
| US202163287952P | 2021-12-09 | 2021-12-09 | |
| US63/287,952 | 2021-12-09 | ||
| US202263302976P | 2022-01-25 | 2022-01-25 | |
| US63/302,976 | 2022-01-25 | ||
| US202263339873P | 2022-05-09 | 2022-05-09 | |
| US63/339,873 | 2022-05-09 | ||
| PCT/US2022/080448 WO2023097291A1 (en) | 2021-11-24 | 2022-11-23 | Complement factor b-modulating compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024541771A JP2024541771A (ja) | 2024-11-12 |
| JP2024541771A5 true JP2024541771A5 (https=) | 2025-12-03 |
Family
ID=86540402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024531113A Pending JP2024541771A (ja) | 2021-11-24 | 2022-11-23 | 補体因子ｂを調節する組成物及びその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12595477B2 (https=) |
| EP (1) | EP4437104A4 (https=) |
| JP (1) | JP2024541771A (https=) |
| KR (1) | KR20240107360A (https=) |
| CN (1) | CN119256083A (https=) |
| AU (1) | AU2022396536A1 (https=) |
| CA (1) | CA3240273A1 (https=) |
| CL (1) | CL2024001561A1 (https=) |
| CO (1) | CO2024006751A2 (https=) |
| IL (1) | IL312928A (https=) |
| MX (1) | MX2024006368A (https=) |
| PE (1) | PE20241340A1 (https=) |
| TW (1) | TW202340463A (https=) |
| WO (1) | WO2023097291A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4684015A2 (en) | 2023-03-21 | 2026-01-28 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of complement factor b (cfb), pharmaceutical compositions thereof, and methods of use |
| CN121532510A (zh) * | 2023-07-28 | 2026-02-13 | 苏州炫景生物科技有限公司 | Cfb抑制剂组合物及其应用 |
| WO2025151250A2 (en) * | 2024-01-09 | 2025-07-17 | Adarx Pharmaceuticals, Inc. | Complement factor b-modulating compositions and methods of use thereof |
| WO2025256564A1 (en) * | 2024-06-12 | 2025-12-18 | Qilu Pharmaceutical Co., Ltd. | iRNA COMPOSITION AND METHOD OF USING SAME |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| WO2005116204A1 (ja) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| KR20150103280A (ko) * | 2013-01-08 | 2015-09-09 | 베니텍 바이오파마 리미티드 | 연령-관련 황반 변성 치료 |
| MY181251A (en) | 2013-09-13 | 2020-12-21 | Ionis Pharmaceuticals Inc | Modulators of complement factor b |
| SG10201804960RA (en) | 2013-12-12 | 2018-07-30 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| EA036496B1 (ru) | 2014-05-01 | 2020-11-17 | Ионис Фармасьютикалз, Инк. | Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b |
| HRP20230127T1 (hr) * | 2017-11-13 | 2023-03-31 | Silence Therapeutics Gmbh | Nukleinske kiseline za inhibiranje ekspresije lpa u stanici |
| JP2023523790A (ja) * | 2020-04-30 | 2023-06-07 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法 |
| WO2023031359A1 (en) | 2021-09-02 | 2023-03-09 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell |
| US20240401045A1 (en) * | 2021-10-01 | 2024-12-05 | Adarx Pharmaceuticals, Inc. | Angiotensinogen-modulating compositions and methods of use thereof |
| CN118302525A (zh) | 2021-10-29 | 2024-07-05 | 阿尔尼拉姆医药品有限公司 | 补体因子B（CFB）iRNA组合物及其使用方法 |
-
2022
- 2022-11-23 AU AU2022396536A patent/AU2022396536A1/en active Pending
- 2022-11-23 CA CA3240273A patent/CA3240273A1/en active Pending
- 2022-11-23 JP JP2024531113A patent/JP2024541771A/ja active Pending
- 2022-11-23 IL IL312928A patent/IL312928A/en unknown
- 2022-11-23 PE PE2024001199A patent/PE20241340A1/es unknown
- 2022-11-23 KR KR1020247020753A patent/KR20240107360A/ko active Pending
- 2022-11-23 WO PCT/US2022/080448 patent/WO2023097291A1/en not_active Ceased
- 2022-11-23 MX MX2024006368A patent/MX2024006368A/es unknown
- 2022-11-23 US US18/058,664 patent/US12595477B2/en active Active
- 2022-11-23 CN CN202280089242.5A patent/CN119256083A/zh active Pending
- 2022-11-23 EP EP22899562.7A patent/EP4437104A4/en active Pending
- 2022-11-24 TW TW111145061A patent/TW202340463A/zh unknown
-
2024
- 2024-05-23 CL CL2024001561A patent/CL2024001561A1/es unknown
- 2024-05-27 CO CONC2024/0006751A patent/CO2024006751A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024541771A5 (https=) | ||
| JP2023548584A5 (https=) | ||
| EP0691977B1 (en) | Oligonucleotides with amide linkages replacing phosphodiester linkages | |
| JP2022519019A5 (https=) | ||
| JP7478210B2 (ja) | 修飾オリゴヌクレオチド及び使用方法 | |
| JP2021074010A5 (https=) | ||
| JP2021515784A5 (https=) | ||
| JP2024536146A5 (https=) | ||
| US20070179112A1 (en) | Polymeric nucleoside prodrugs | |
| TW202330035A (zh) | 治療性化合物之標靶性配體 | |
| JP2024079716A5 (https=) | ||
| JP2009524696A5 (https=) | ||
| JP2021072862A5 (https=) | ||
| JP2021090458A5 (https=) | ||
| JP2020511155A5 (https=) | ||
| IL277970B1 (en) | Oligomeric compounds comprising modified oligonucleotides and conjugate groups for use in treating end stage renal disease, chronic kidney disease, and coronary artery disease | |
| JP2021522804A5 (https=) | ||
| AR127325A1 (es) | Métodos y composiciones para el tratamiento de la enfermedad renal poliquística | |
| TW202304474A (zh) | 用於抑制晚期糖化終產物之受體表現之RNAi藥劑、其組合物及使用方法 | |
| TW201920671A (zh) | 單股寡核苷酸 | |
| JP2024534157A5 (https=) | ||
| JP2025511183A5 (https=) | ||
| JPH08508489A (ja) | 二官能価ヌクレオシド、それらのオリゴマーならびにそれらの製造方法及び使用方法 | |
| JP2000512630A (ja) | ２’―置換ヌクレオシドおよびオリゴヌクレオチド誘導体 | |
| CN119137272A (zh) | 血管紧张素原调节组合物和其使用方法 |